332 related articles for article (PubMed ID: 31923859)
21. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
Chen Y; Ernst P
Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction.
Karatas H; Townsend EC; Bernard D; Dou Y; Wang S
J Med Chem; 2010 Jul; 53(14):5179-85. PubMed ID: 20575550
[TBL] [Abstract][Full Text] [Related]
23. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5.
Senisterra G; Wu H; Allali-Hassani A; Wasney GA; Barsyte-Lovejoy D; Dombrovski L; Dong A; Nguyen KT; Smil D; Bolshan Y; Hajian T; He H; Seitova A; Chau I; Li F; Poda G; Couture JF; Brown PJ; Al-Awar R; Schapira M; Arrowsmith CH; Vedadi M
Biochem J; 2013 Jan; 449(1):151-9. PubMed ID: 22989411
[TBL] [Abstract][Full Text] [Related]
24. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
[TBL] [Abstract][Full Text] [Related]
25. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
26. On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex.
Patel A; Dharmarajan V; Vought VE; Cosgrove MS
J Biol Chem; 2009 Sep; 284(36):24242-56. PubMed ID: 19556245
[TBL] [Abstract][Full Text] [Related]
27. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
28. Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.
Li BE; Ernst P
Exp Hematol; 2014 Dec; 42(12):995-1012. PubMed ID: 25264566
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
30. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
31. Targeting human SET1/MLL family of proteins.
Vedadi M; Blazer L; Eram MS; Barsyte-Lovejoy D; Arrowsmith CH; Hajian T
Protein Sci; 2017 Apr; 26(4):662-676. PubMed ID: 28160335
[TBL] [Abstract][Full Text] [Related]
32. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance.
Huo H; Magro PG; Pietsch EC; Patel BB; Scotto KW
Cancer Res; 2010 Nov; 70(21):8726-35. PubMed ID: 20861184
[TBL] [Abstract][Full Text] [Related]
33. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
[TBL] [Abstract][Full Text] [Related]
34. MLL1/WDR5 complex in leukemogenesis and epigenetic regulation.
Wu M; Shu HB
Chin J Cancer; 2011 Apr; 30(4):240-6. PubMed ID: 21439245
[TBL] [Abstract][Full Text] [Related]
35. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
Heikamp EB; Henrich JA; Perner F; Wong EM; Hatton C; Wen Y; Barwe SP; Gopalakrishnapillai A; Xu H; Uckelmann HJ; Takao S; Kazansky Y; Pikman Y; McGeehan GM; Kolb EA; Kentsis A; Armstrong SA
Blood; 2022 Feb; 139(6):894-906. PubMed ID: 34582559
[TBL] [Abstract][Full Text] [Related]
36. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
[TBL] [Abstract][Full Text] [Related]
37. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.
Klossowski S; Miao H; Kempinska K; Wu T; Purohit T; Kim E; Linhares BM; Chen D; Jih G; Perkey E; Huang H; He M; Wen B; Wang Y; Yu K; Lee SC; Danet-Desnoyers G; Trotman W; Kandarpa M; Cotton A; Abdel-Wahab O; Lei H; Dou Y; Guzman M; Peterson L; Gruber T; Choi S; Sun D; Ren P; Li LS; Liu Y; Burrows F; Maillard I; Cierpicki T; Grembecka J
J Clin Invest; 2020 Feb; 130(2):981-997. PubMed ID: 31855575
[TBL] [Abstract][Full Text] [Related]
38. WDR5 interacts with mixed lineage leukemia (MLL) protein via the histone H3-binding pocket.
Song JJ; Kingston RE
J Biol Chem; 2008 Dec; 283(50):35258-64. PubMed ID: 18840606
[TBL] [Abstract][Full Text] [Related]
39. MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia.
Chen Y; Anastassiadis K; Kranz A; Stewart AF; Arndt K; Waskow C; Yokoyama A; Jones K; Neff T; Lee Y; Ernst P
Cancer Cell; 2017 Jun; 31(6):755-770.e6. PubMed ID: 28609655
[TBL] [Abstract][Full Text] [Related]
40. Structure of WDR5 bound to mixed lineage leukemia protein-1 peptide.
Patel A; Dharmarajan V; Cosgrove MS
J Biol Chem; 2008 Nov; 283(47):32158-61. PubMed ID: 18829459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]